PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28465296-8	2017	A subset of tumors had significantly elevated SLC35F2 expression and, therefore, may identify patients who are highly responsive to YM155 treatment.	YM 155	132-137	solute carrier family 35 member F2	Homo sapiens	46-53	
28465296-9	2017	IMPLICATIONS: The combination of androgen therapy with YM155 represents a novel drug synergy, and SLC35F2 may serve as a clinical biomarker of response to YM155.	YM 155	155-160	solute carrier family 35 member F2	Homo sapiens	98-105	
33418944-8	2021	In conclusion, we suggest that SLC35F2 is involved in bladder cancer progression and might provide a new therapeutic approach, for example, by the anti-cancer drug YM155, a cargo of the SLC35F2 transporter.	YM 155	164-169	solute carrier family 35 member F2	Homo sapiens	31-38	
25064833-0	2014	The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity.	YM 155	35-40	solute carrier family 35 member F2	Homo sapiens	19-26	
34815782-0	2021	USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2.	YM 155	40-45	solute carrier family 35 member F2	Homo sapiens	112-119	
34815782-7	2021	Results: CRISPR-based dual-screening method identified USP32 as a novel DUB that governs resistance for uptake of YM155 by destabilizing protein levels of SLC35F2, a solute-carrier protein essential for the uptake of YM155.	YM 155	114-119	solute carrier family 35 member F2	Homo sapiens	155-162	
34815782-7	2021	Results: CRISPR-based dual-screening method identified USP32 as a novel DUB that governs resistance for uptake of YM155 by destabilizing protein levels of SLC35F2, a solute-carrier protein essential for the uptake of YM155.	YM 155	217-222	solute carrier family 35 member F2	Homo sapiens	155-162	
33831396-8	2021	The increase in SLC35F2 expression led to an increase in the sensitivity of U937/HQ cells to YM155-mediated cytotoxicity, whereas no shuch effect was observed in HL-60/HQ cells.	YM 155	93-98	solute carrier family 35 member F2	Homo sapiens	16-23	
33831396-11	2021	In addition, our data indicate that SLC35F2 increases the sensitivity of U937 cells to YM155-mediated cytotoxicity, whereas MPO enhances YM155 cytotoxicity in U937 and HL-60 cells.	YM 155	87-92	solute carrier family 35 member F2	Homo sapiens	36-43	
33418944-8	2021	In conclusion, we suggest that SLC35F2 is involved in bladder cancer progression and might provide a new therapeutic approach, for example, by the anti-cancer drug YM155, a cargo of the SLC35F2 transporter.	YM 155	164-169	solute carrier family 35 member F2	Homo sapiens	186-193	
33144341-4	2021	SLC35F2 activity was assessed using its substrate, YM155, and pharmacological experiments revealed SLC35F2 inhibitors, such as famotidine (half-maximal inhibitory concentration, 160 muM).	YM 155	51-56	solute carrier family 35 member F2	Homo sapiens	0-7	
33144341-5	2021	Uptake of YM155 was decreased by famotidine or SLC35F2 siRNA transfection in immortalized human BMECs (hCMEC/D3 cells).	YM 155	10-15	solute carrier family 35 member F2	Homo sapiens	47-54	
33144341-7	2021	Crucially, SLC35F2-knockout diminished the A-to-B transport and intracellular accumulation of YM155 in hiPS-BMECs.	YM 155	94-99	solute carrier family 35 member F2	Homo sapiens	11-18	
31157201-4	2019	We found that a hydrogen bond acceptor in the pyrazine ring of YM155 derivatives is critical for stemotoxic activity, which is completely lost in hESCs lacking SLC35F2, which encodes a solute carrier protein.	YM 155	63-68	solute carrier family 35 member F2	Homo sapiens	160-167	
32916603-4	2020	In this study, we demonstrated that the high cytotoxicity of YM155 in hPSCs, which is mediated by selective cellular uptake of the drug, is due to the high expression of SLC35F2 in these cells.	YM 155	61-66	solute carrier family 35 member F2	Homo sapiens	170-177	
32916603-5	2020	Knockout of SLC35F2 with CRISPR-Cas9, or depletion with siRNAs, made the hPSCs highly resistant to YM155.	YM 155	99-104	solute carrier family 35 member F2	Homo sapiens	12-19	
32357518-2	2020	Findings from one YM155-adapted subline of the neuroblastoma cell line UKF-NB-3 had suggested that increased ABCB1 (mediates YM155 efflux) levels, decreased SLC35F2 (mediates YM155 uptake) levels, decreased survivin levels, and TP53 mutations indicate YM155 resistance.	YM 155	18-23	solute carrier family 35 member F2	Homo sapiens	157-164